Mov­ing on from Us­ama Ma­lik's in­sid­er trad­ing im­broglio, Fore re­sets at the top; Take­da spin­out turns to Neu­rana CEO to lead the way

→ The ouster of for­mer Im­munomedics ex­ec Us­ama Ma­lik cre­at­ed a CEO open­ing at Fore Bio­ther­a­peu­tics, which is tak­ing aim at BRAF mu­ta­tions fol­low­ing a re­brand last year. Matthew Ros has now stepped up to the tee box as CEO and a mem­ber of the board af­ter Ma­lik was em­broiled in an in­sid­er trad­ing scan­dal dur­ing his time at Im­munomedics that he chose to ad­dress in a rather cryp­tic LinkedIn post in De­cem­ber. A 17-year Bris­tol My­ers Squibb vet, Ros left Sanofi Gen­zyme in 2016 to be­come COO of Epizyme, where he had since been chief strat­e­gy and busi­ness of­fi­cer. Fore Bio, once known as di­ag­nos­tics com­pa­ny Nov­el­lus­Dx and chaired by for­mer Sanofi ex­ec Di­eter Weinand, is in a Phase I/IIa tri­al with its lead can­di­date FORE8394.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER